Table 1.
Included large-scale gene expression profiling studies on brain tissue from epilepsy surgery
| Name | Test tissue | Control tissue | Chip | Number of regulated genes |
|---|---|---|---|---|
| Lee et al. (13) | Sclerosed CA1 from MTLE (n = 8) | Histologically normal CA1 from MaTLE (n = 6) or PTLE (n = 6) | Affymetrix U133A | 674 (MTLE versus PTLE and MTLE versus MaTLE); 947 (MTLE versus others) |
| van Gassen et al. (11) | Sclerosed hippocampus from MTLE patients (n = 4) | Hippocampus from MTLE patients without HS (n = 4) and autopsy (n = 4) | Human Array-Ready oligo set version 2.0, Operon Biotechnologies | Autopsy versus non-HS: 322; Autopsy versus HS: 322; non-HS versus HS: 206 |
| Xi et al. (14) | Anterior temporal neocortex epileptogenic zone (n = 40) | Anterior temporal neocortex removed for raised ICP (n = 20) | n.s. | 143 |
| Ozbas-Gerceker et al. (15) | Anterior hippocampus (n = 6) | Anterior hippocampus tissue from autopsy (n = 1) | SAGE | 143 |
| Xiao et al. (16) | Temporal lobe (n = 40): HS, FCD etc. | Temporal neocortex, hippocampus, parietal cortex or frontal cortex from brain trauma patients (n = 20) | Biostar H-40s | 142 |
| Arion et al. (17) | ‘Spiking areas’ from anterolateral temporal cortical samples (n = 6) | ‘Non-spiking’ from anterolateral temporal cortical samples (n = 6) | Affymetrix U133A | 76 |
| Becker et al. (19) | Sclerosed CA1 from MTLE (n = 5) | Dentate gyrus from same patients (n = 5) | Affymetrix U133A | 25 |
| Becker et al. (19) | Sclerosed hippocampus (n = 3) | Normal hippocampus from tumour patients (n = 2) or epilepsy patients (n = 1) | Atlas, Clontech | 21 |
| Jamali et al. (20) | Entorhinal cortex (n = 5) | Lateral temporal neocortex (n = 5) | Micromax | 16 |
FCD, focal cortical dysplasia; HS, hippocampal sclerosis; ICP, intracranial pressure; IE, intractable epilepsy; MaTLE, mass-associated temporal lobe epilepsy; MTLE, mesial temporal lobe epilepsy; n.s., not specified; PTLE, paradoxical temporal lobe epilepsy; SAGE, serial analysis of gene expression.